Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial

IMPORTANCE: Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In a phase 2 study, an overall survival benefit in this population was observed with the addition of olaratumab to doxorubicin over doxorubicin alone. OBJECTIVE: To determine the efficac...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:JAMA
Huvudupphovsmän: Tap, William D., Wagner, Andrew J., Schöffski, Patrick, Martin-Broto, Javier, Krarup-Hansen, Anders, Ganjoo, Kristen N., Yen, Chueh-Chuan, Abdul Razak, Albiruni R., Spira, Alexander, Kawai, Akira, Le Cesne, Axel, Van Tine, Brian A., Naito, Yoichi, Park, Se Hoon, Fedenko, Alexander, Pápai, Zsuzsanna, Soldatenkova, Victoria, Shahir, Ashwin, Mo, Gary, Wright, Jennifer, Jones, Robin L.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Medical Association 2020
Ämnen:
Original Investigation
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7139275/
https://ncbi.nlm.nih.gov/pubmed/32259228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2020.1707
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk